Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One Course Adjuvant BEP vs Carboplatin in Clinical Stage I Seminoma
2024-518399-29-00Phase 3Authorised
- Sponsor
- St. Olavs University Hospital
- Start
- Dec 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of carboplatin, bleomycin, cisplatin and etoposide in Pure seminoma (2 arms), sponsored by St. Olavs University Hospital. Primary endpoint: Relapse rate. Planned start Dec 2024; status: authorised.
02
Drugs
carboplatinbleomycincisplatinetoposide
03
Conditions
Pure seminoma
Beyond the preview
Go deeper on 2024-518399-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518399-29-00.